Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19

A Multi-centre, Adaptive, Randomized, Double-blind, Placebo-controlled Comparative Clinical Study of the Safety and Efficacy of Polyoxidonium®, Lyophilizate for Solution for Injections and Topical Application, 6 mg (NPO Petrovax Pharm LLC, Russia) in Patients With Coronavirus Disease (COVID-19).

The purpose of this study is to demonstrate the superiority of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). This is a multicentre prospective, randomized, double-blind, placebo-controlled, parallel-group phase IIb\IIIa clinical trial.

Study Overview

• Status: Active, not recruiting
• Conditions: Infections, Coronavirus
• Intervention / Treatment: Other: Placebo; Drug: azoximer bromide

Detailed Description

This is a multicenter prospective, randomized, double-blind, placebo-controlled, parallel-group phase 3 IIb\IIIa trial to evaluate the efficacy of Polyoxidonium®, lyophilizate for solution for injections and topical application, 6 mg over placebo in hospitalized patients with coronavirus disease (COVID-19). A study will last for 29±3 days (maximum) for each participant and will include: screening (days -1...1); treatment period (17 days in total, days 1...17) with the administration of the investigational product Polyoxidonium/placebo (intravenous injections for 3 days, then intramuscular injections for 14 days), assessment of the clinical status, recording of AEs; follow-up period (days 18...29±3).

Haematology and blood chemistry tests will be performed at day -1 and days 1,3, 8 ±1, 17±1.

Assessment of the clinical status according to the 7-point ordinal scale and according to the National Early Warning Score (NEWS) scale will be done every day during hospitalization from day 1 up to and including day 17 and at the follow-up on day 29±3.

The safety and tolerability will be evaluated throughout the study (from signing the Informed Consent Form to the study completion visit).

• Study Type: Interventional
• Enrollment (Actual): 394
• Phase: Phase 2; Phase 3

Contacts and Locations

Study Locations

• Russian Federation
  • Barnaul, Russian Federation, 656045
    • Regional state budgetary institution of public health "City hospital No. 5 of Barnaul"
  • Moscow, Russian Federation, 111123
    • Central Research Institute of Epidemiology of Rospotrebnadzor
  • Moscow, Russian Federation, 111539
    • The state healthcare institution of the city of Moscow "City Clinical Hospital No. 15 named after OM Filatov" in "Moscow City Department of Health"
  • Moscow, Russian Federation, 125367
    • Moscow State Budgetary Healthcare Institution "Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare"
  • Moscow, Russian Federation, 127015
    • Moscow State Budgetary Healthcare Institution "City Clinical Hospital No. 24 of the Moscow Department of Healthcare"
  • Moscow, Russian Federation, 129090
    • State budgetary institution "Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow"
  • Moscow, Russian Federation, 129301
    • Moscow State Budgetary Healthcare Institution "City Clinical Hospital No. 40 of the Moscow Department of Healthcare"
  • Nizhny Novgorod, Russian Federation, 603022
    • State budgetary institution of health care of the Nizhny Novgorod region "Infectious clinical hospital No. 2 of Nizhny Novgorod"
  • Orenburg, Russian Federation, 460000
    • Federal State Budgetary Educational Institution of Higher Education "Orenburg State Medical University" of the Ministry of Health of the Russian Federation
  • Saint Petersburg, Russian Federation, 197022
    • Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I.P. Pavlov
  • Vladimir, Russian Federation, 600023
    • State budgetary health institution of the Vladimir region "Regional Clinical Hospital"
  • Yaroslavl, Russian Federation, 150000
    • Yaroslavl State Medical University of Ministry of Health of the Russian Federation
• Slovakia
  • Nitra, Slovakia, 949 01
    • Clinics of Infectious Diseases, University Hospital in Nitra
  • Trnava, Slovakia, 917 74
    • Clinics of Infectious Diseases, University Hospital in Trnava

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 83 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male and female patients from 18 to 85 years of age.
2. The patient (or his/her legal representative, if the patient is not able to sign the form) signed an Informed Consent form for participation in this study before any initiation of any study procedures.
3. The patient can understand all protocol requirements, perform the study procedures, and agree to all limitations specified in the protocol.
4. Confirmed diagnosis of coronavirus disease (COVID-19): laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 14 days prior to randomization.

5. Illness (coronavirus disease COVID-19) of any duration, and at least one of the following:

   • Radiographic/tomographic chest infiltrates by imaging (chest x-ray, CT scan, etc.), OR
   • Evidence of rales/crackles on clinical exam AND SpO2 ≤ 94% on room air, OR
   • Indications for mechanical ventilation and/or supplemental oxygen.
6. Agrees to use adequate contraception methods (the methods with at least 90% efficacy include non-hormonal intrauterine devices; condom with intravaginal spermicide; cervical caps

Exclusion Criteria:

1. History of clinically significant allergic reactions.
2. Hypersensitivity and/or intolerability to any ingredient of the investigational product or placebo.
3. Anticipated transfer to another hospital which is not a study centre within the next 72 hours.
4. Acute or chronic renal failure.
5. History of HIV infection, tuberculosis.
6. Conditions associated with primary immunodeficiency.
7. Concomitant use of cytostatic medications to treat a concomitant disease.
8. Systemic connective tissue diseases.
9. Need for the prohibited medications.
10. Administration of medications that are prohibited or unauthorized by the protocol within 2 weeks before the expected randomization date.
11. History of alcohol or drug dependence.
12. History of malignant tumours of any location with remission for less than 2 years.
13. History of psychic (including depressive) disorders, physical and other factors that do not allow for adequate self-assessment of one's behaviour and for compliance with the protocol requirements, including history of psychiatric disorders.
14. Pregnancy or breastfeeding.
15. Intravenous injections and/or sampling of the required amount of blood is not possible.
16. Positive pregnancy test (in patients with childbearing potential).
17. Participation in any clinical study within 3 months before enrolment in this study.
18. History of any condition that the study doctor considers significant enough to prevent enrolment of this patient.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Polyoxidonium; Polyoxidonium will be administered in the dose of 12 mg (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).	Drug: azoximer bromide; Investigational medicinal product; Other Names: Polyoxidonium
Placebo Comparator: Placebo; Placebo will be administered (contents of 2 vials) once daily intravenously (IV) for 3 days, then every other day intramuscularly (IM) on days 5-17 (the total treatment course is 10 injections).	Other: Placebo; Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical status of the patient (according to 7-point ordinal scale)	The primary efficacy outcome will be defined based on the blinded analysis of data of the first 100 patients in the 1st part of the study. There is uncertainty about the clinical course and potential different trajectories according to baseline disease severity, so the day of the primary endpoint may be modified based on a blinded evaluation of the primary efficacy outcome in various days.	Day 15

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical status of the patient (according to 7-point ordinal scale)	Time to improvement by one category from admission on the ordinal scale. Clinical status of the patient. Average change in the ordinal scale from baseline.	Clinical status of the patient and the average change in the ordinal scale from baseline, both on days 3, 5, 8, 11, 29.
NEWS	The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first. Change in NEWS from baseline.	Change in NEWS from baseline on days 3, 5, 8, 11, 15, 29.
Oxygenation	Oxygenation free days. Incidence and duration of new oxygen use.	Oxygenation free days in the first 28 days (to day 29). Incidence and duration of new oxygen use during the study.
Mechanical Ventilation	Ventilator free days. Incidence and duration of new mechanical ventilation use.	Ventilator free days in the first 28 days (to day 29). Incidence and duration of new mechanical ventilation use during the trial.
Mortality		28-day mortality

Collaborators and Investigators

• Sponsor: NPO Petrovax
• Investigators: Principal Investigator: Jean-Francois Rossi, Professor, University of Montpellier (Faculté de Médecine) and Institute Sainte Catherine

Study record dates

Study Major Dates

• Study Start (Actual): April 29, 2020
• Primary Completion (Anticipated): April 1, 2021
• Study Completion (Anticipated): April 1, 2021

Study Registration Dates

• First Submitted: May 7, 2020
• First Submitted That Met QC Criteria: May 7, 2020
• First Posted (Actual): May 8, 2020

Study Record Updates

• Last Update Posted (Actual): February 16, 2021
• Last Update Submitted That Met QC Criteria: February 15, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: COVID-19
• Additional Relevant MeSH Terms: Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Coronavirus Infections; Anticonvulsants; Bromides
• Other Study ID Numbers: PО-COV-III-20

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No